Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Primary Immunodeficiency Disorders Industry Compare Between 2025 And 2029?
The market size for primary immunodeficiency disorders has experienced robust growth in recent years. It is projected to increase from $6.84 billion in 2024 to $7.3 billion in 2025, at a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to the rising prevalence of primary immunodeficiency disorders, heightened awareness among healthcare professionals, a growing need for effective treatments, increased funding for research, and an intensifying focus on pediatric care.
The market for primary immunodeficiency disorders is projected to experience substantial expansion in the upcoming years. This market is anticipated to reach $9.43 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. Several factors will drive this growth during the projection period, including the increased adoption of subcutaneous treatments, enhanced healthcare accessibility, strong research and development efforts, a heightened demand for effective therapies, and an increasing need for immunoglobulin replacement therapy. Key trends expected over the forecast period encompass progress in biotechnology, groundbreaking gene therapies and biologics, developments in genetic testing and individualized medicine, advancements in gene therapy, and improvements in genetic diagnostic tests.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp
What Are The Top Growth Drivers Impacting The Primary Immunodeficiency Disorders Market Outlook?
The increasing occurrence of autoimmune diseases is anticipated to propel the expansion of the primary immunodeficiency disorders market moving forward. Autoimmune diseases manifest when the immune system erroneously attacks the body’s healthy cells and tissues, perceiving them as foreign threats. This aberrant response leads to inflammation and damage across various organs and systems. The surge in autoimmune diseases is attributed to a complex interplay of environmental factors, genetic predispositions, and shifts in lifestyle. Autoimmune conditions can instigate primary immunodeficiency disorders by disrupting immune regulation and targeting immune cells, which results in weakened or impaired immune responses. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based interactive online platform, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, leading to a raw prevalence rate of 8.61%. Thus, the rising prevalence of autoimmune diseases is driving the growth of the primary immunodeficiency disorders market.
What Are The Key Segments In The Primary Immunodeficiency Disorders Market?
The primary immunodeficiency disordersmarket covered in this report is segmented –
1) By Disease: Antibody Deficiency; Cellular Immunodeficiency; Innate Immune Disorders; Other Diseases
2) By Treatment: Immunoglobulin Replacement Therapy; Antibiotic Therapy; Stem Cell And Bone Marrow Transplantation; Gene Therapy; Other Treatments
3) By Diagnostic Type: Genetic Testing; Blood Testing; Flow Cytometry; Other Diagnostic Types
4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Research Institutions
Subsegments:
1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID); IgA Deficiency; IgG Subclass Deficiency; Specific Antibody Deficiency
2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID); T-Cell Deficiency; DiGeorge Syndrome; Wiskott-Aldrich Syndrome
3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD); Complement Deficiencies; Toll-like Receptor Deficiencies; Chediak-Higashi Syndrome
4) By Other Diseases: Hyper IgM Syndrome; Hyper IgE Syndrome; Ataxia-Telangiectasia; Combined Immunodeficiencies With Syndromic Features
What Key Innovation Trends Are Fueling Advancements In The Primary Immunodeficiency Disorders Market?
Major companies engaged in the primary immunodeficiency disorders market are prioritizing the creation of advanced treatments, including intravenous immunoglobulin therapy, to enhance patient results by boosting immune function. Intravenous immunoglobulin (IVIG) therapy is a medical procedure where immunoglobulin (antibodies) obtained from donor plasma are administered directly into a patient’s circulatory system intravenously. For example, in June 2024, Grifols, a Spain-based healthcare company, secured FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This recently developed, sugar-free, and pre-prepared IgG solution is sourced from human blood plasma and is intended for intravenous administration. Approved in the U.S. for substitution therapy in individuals with primary antibody deficiency syndromes, Yimmugo offers antibody replacement to support those with deficiencies in their immune systems. It also expands Grifols’ selection of plasma-based treatments by providing a safer and more effective option to help protect against infections.
Who Are The Primary Competitors In The Global Primary Immunodeficiency Disorders Market?
Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., Chengdu Rongsheng Pharmaceutical Co Ltd.
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Primary Immunodeficiency Disorders Market During The Forecast Period?
North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Primary Immunodeficiency Disorders Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23483&type=smp
Browse Through More Reports Similar to the Global Primary Immunodeficiency Disorders Market 2025, By The Business Research Company
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025
Drugs For Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Lateral Flow Immunoassay Based Rapid Test Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model